. Author manuscript; available in PMC: 2020 Jun 1.

Published in final edited form as: Cancer Prev Res (Phila). 2019 Apr 23;12(6):401–412. doi: 10.1158/1940-6207.CAPR-18-0383

Table 2A.

TGF-β Isoform Expression in Ovarian and Fallopian Tube Epithelium in Subjects with and without Levonorgestrel Treatment

Tissue	TGF-β isoform	Treatment	Mean stain intensity ± SD (95% CI)	p-value
Ovary	TGF-β1	Placebo	0.95 ± 1.11 (0.43, 1.47)
Ovary	TGF-β1	Levonorgestrel	1.46 ± 1.22 (0.99, 1.92)	0.139
	TGF-β2	Placebo	2.29 ± 1.01 (1.89, 2.68)
	TGF-β2	Levonorgestrel	2.32 ± 1.09 (1.90, 2.74)	0.899
	TGF-β3	Placebo	1.50 ± 1.31 (1.01, 1.99)
	TGF-β3	Levonorgestrel	1.52 ± 1.26 (1.05, 1.98)	0.961
Fallopian Tube	TGF-β1	Placebo	1.67 ± 1.15 (1.21, 2.14)
Fallopian Tube	TGF-β1	Levonorgestrel	2.12 ± 1.33 (1.63, 2.63)	0.185
	TGF-β2	Placebo	2.45 ± 1.05 (2.06, 2.84)
	TGF-β2	Levonorgestrel	2.67 ± 0.90 (2.35, 2.99)	0.374
	TGF-β3	Placebo	2.25 ± 1.02 (1.87, 2.63)
	TGF-β3	Levonorgestrel	2.16 ± 1.26 (1.70, 2.61)	0.748